ERBB2 and lung adenocarcinoma: Consistent with known clinicopathological features of oncogene-driven NSCLC, cohort A had more women (65%), Asians (50%), and lung adenocarcinomas (97%) compared to cohorts B and C. Driver oncogene mutations included EGFR mutations (N = 24, 70.6%), ALK fusions (N = 3, 8.8%), HER2 alterations (N = 3, 8.8%), MET alterations (N = 3, 8.8%) and RET fusion (N = 1, 2.9%).